Clinical trials for advancing innovative interventions for neurodegenerative diseases[E8]

公告より

Call: Cluster 1 - Health (Two stage - 2027). Type of action: HORIZON Research and Innovation Actions. Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: The scientific and clinical communities make effective use of state-of-the-art knowledge, data, technologies, tools, methods, best practices, and trainings to underpin and complement the development of innovative interventions aimed at more effective treatments for neurodegenerative diseases. The scientific and clinical communities benefit from the exchange of data, knowledge and best practices, thereby strengthening their collaboration in the EU, the Associated Countries and beyond. The scientific and clinical communities make wide use of relevant databases and/or integrate them with existing infrastructures for storage and sharing of collected data according to FAIR [1] principles, thereby encouraging further use of the data. Policymakers, funders, scientific and clinical communities, patient organisations, regulators, and other relevant bodies are informed of the research advances made and the requirements for a widespread implementation of the innovative therapeutic interventions and complementary approaches. Patients and caregivers are constructively engaged with the research, ensuring that their needs are catered for…[E3]

公告の詳細は情報源が公開したとおりに表示しています。当社が抽出する事実と要件は英語で記載しています。

• 対象Universities and research. 掲載文の言葉から SLETOR が分類しました。
• 条件EU grant rules apply: check the call conditions for who can apply, consortium rules and co-funding.[E4]

• リスクThis is a grant, not a contract. Grants usually need a proposal against the funder's criteria, may need partners and often need co-funding.[E5]
• 不明We read the funder's listing, not the full guidance or application forms.

1. 入札受付開始 · 2026年10月29日, 07:41 UTC

   The funder published the call with a future closing date.

   変更：status, notice type, published at (元の記録 Clinical trials for advancing innovative interventions for neurodegenerative di… (ID HORIZON-HLTH-2027-02-DISEASE-14-two-stage))

2. 初回取得 · 2026年10月28日, 21:22 UTC

   The funder announced the call. Applications have not opened yet.

   元の記録: Clinical trials for advancing innovative interventions for neurodegenerative di… (ID HORIZON-HLTH-2027-02-DISEASE-14-two-stage)

このページの情報はすべて資金提供者の掲載情報からのものです。各項目に読み取った記録と項目名を示します。

1. E1

   The funder is European Commission.

   出典: Clinical trials for advancing innovative interventions for neurodegenerative di… (ID HORIZON-HLTH-2027-02-DISEASE-14-two-stage)、 項目 /metadata/type/0, 2026年10月29日, 07:41 UTCに読み取り · 情報源 ↗ （新しいタブで開きます）

2. E2

   Proposals must be submitted by 17 Feb 2027, 01:00 Central European time (UTC+1).

   “2027-02-17T00:00:00.000+0000”

   出典: Clinical trials for advancing innovative interventions for neurodegenerative di… (ID HORIZON-HLTH-2027-02-DISEASE-14-two-stage)、 項目 /metadata/deadlineDate/0, 2026年10月29日, 07:41 UTCに読み取り · 情報源 ↗ （新しいタブで開きます）

3. E3

   The buyer describes the requirement in the notice.

   “Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed…”

   出典: Clinical trials for advancing innovative interventions for neurodegenerative di… (ID HORIZON-HLTH-2027-02-DISEASE-14-two-stage)、 項目 /metadata/descriptionByte/0, 2026年10月29日, 07:41 UTCに読み取り · 情報源 ↗ （新しいタブで開きます）

4. E4

   EU grant rules apply: check the call conditions for who can apply, consortium rules and co-funding.

   “EU call topic”

   出典: Clinical trials for advancing innovative interventions for neurodegenerative di… (ID HORIZON-HLTH-2027-02-DISEASE-14-two-stage)、 項目 /metadata/type/0, 2026年10月29日, 07:41 UTCに読み取り · 情報源 ↗ （新しいタブで開きます）

5. E5

   This is an EU call for proposals.

   “31094502”

   出典: Clinical trials for advancing innovative interventions for neurodegenerative di… (ID HORIZON-HLTH-2027-02-DISEASE-14-two-stage)、 項目 /metadata/status/0, 2026年10月29日, 07:41 UTCに読み取り · 情報源 ↗ （新しいタブで開きます）

6. E6

   Applications open on 29 Oct 2026.

   “2026-10-29T00:00:00.000+0000”

   出典: Clinical trials for advancing innovative interventions for neurodegenerative di… (ID HORIZON-HLTH-2027-02-DISEASE-14-two-stage)、 項目 /metadata/startDate/0, 2026年10月29日, 07:41 UTCに読み取り · 情報源 ↗ （新しいタブで開きます）

7. E7

   The Funding & Tenders Portal gives the status as open for submission.

   出典: Clinical trials for advancing innovative interventions for neurodegenerative di… (ID HORIZON-HLTH-2027-02-DISEASE-14-two-stage)、 項目 /metadata/status/0, 2026年10月29日, 07:41 UTCに読み取り · 情報源 ↗ （新しいタブで開きます）

8. E8

   The notice is titled "Clinical trials for advancing innovative interventions for neurodegenerative diseases".

   出典: Clinical trials for advancing innovative interventions for neurodegenerative di… (ID HORIZON-HLTH-2027-02-DISEASE-14-two-stage)、 項目 /metadata/title/0, 2026年10月29日, 07:41 UTCに読み取り · 情報源 ↗ （新しいタブで開きます）

9. E9

   The EU contribution per grant is up to EUR 10,000,000 (from EUR 5,000,000).

   出典: Clinical trials for advancing innovative interventions for neurodegenerative di… (ID HORIZON-HLTH-2027-02-DISEASE-14-two-stage)、 項目 /metadata/budgetOverview/0, 2026年10月29日, 07:41 UTCに読み取り · 情報源 ↗ （新しいタブで開きます）

Source: EU Funding & Tenders Portal, © European Union, CC BY 4.0. SLETOR shortened and reformatted the text. データのライセンス： Creative Commons Attribution 4.0 (European Commission) ↗ （新しいタブで開きます）. 公告に含まれる個人の連絡先は保存も表示もしません。